Marshall University

Marshall Digital Scholar
Pharmaceutical Science and Research

Faculty Research

3-5-2018

Topical Digitoxigenin for Wound Healing: A Feasibility Study
Xinchi Feng
Cuifen Wang
Yunhui Xu
Joel Turley
Zijian Xie

See next page for additional authors

Follow this and additional works at: https://mds.marshall.edu/sp_psr
Part of the Medicinal and Pharmaceutical Chemistry Commons

Authors
Xinchi Feng, Cuifen Wang, Yunhui Xu, Joel Turley, Zijian Xie, Sandrine Pierre, and Jinsong Hao

bioengineering
Article

Topical Digitoxigenin for Wound Healing:
A Feasibility Study
Xinchi Feng 1,2 , Cuifen Wang 1 , Yunhui Xu 3 , Joel Turley 1 , Zijian Xie 3 , Sandrine V. Pierre 3
and Jinsong Hao 1,3, *
1

2
3

*

Department of Pharmaceutical Science and Research, School of Pharmacy, Marshall University, One John
Marshall Drive, Huntington, WV 25755, USA; xiaochi0211@163.com (X.F.); wangc@marshall.edu (C.W.);
turley37@live.marshall.edu (J.T.)
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
Marshall Institute for Interdisciplinary Research, Marshall University, Huntington, WV 25703, USA;
xuy@marshall.edu (Y.X.); xiez@marshall.edu (Z.X.); pierres@marshall.edu (S.V.P.)
Correspondence: haoj@marshall.edu; Tel.: +1-304-696-3519

Received: 5 February 2018; Accepted: 2 March 2018; Published: 5 March 2018

Abstract: (1) Background: Cardiotonic steroids have been found to stimulate collagen synthesis
and might be potential wound healing therapeutics. The objective of this study was to evaluate the
feasibility of digitoxigenin and its topical formulation for wound healing; (2) Methods: In the in vitro
study, the human dermal fibroblast cells were treated with digitoxigenin and collagen synthesis
was assessed. In the in vivo study, digitoxigenin was applied to excisional full-thickness wounds
in rats immediately after wounding and remained for three days, and wound open was evaluated
over 10 days. A digitoxigenin formulation for topical administration was prepared, and the in vitro
release and in vivo wound healing effect were investigated; (3) Results: The expression of procollagen
in human dermal fibroblast was significantly increased with the exposure to 0.1 nM digitoxigenin.
Topical application of digitoxigenin in olive oil or alginate solution for three days significantly
decreased the wound open in rats. Similarly, topical administration of the developed digitoxigenin
formulation for three days also significantly increased wound healing. No wound healing effects were
observed at days 7 and 10 after wounding when digitoxigenin was not applied; and, (4) Conclusions:
It was possible to deliver digitoxigenin using the developed formulation. However, the wound
healing effect of digitoxigenin and its mechanisms need to be further investigated in future studies.
Keywords: digitoxigenin; wound healing; full-thickness excision wound; human dermal fibroblast;
alginate

1. Introduction
Chronic wounds are one of the major clinical challenges in the world. It is estimated that the
annual cost on the treatment of chronic wounds is over $25 billion [1]. Due to aging population and
increased number of people with diabetes and obesity worldwide, the financial burden of treating
chronic wounds is increasing. Current treatment options of chronic wounds are less effective. Thus,
there is an urgent need for the development of novel wound healing therapeutics. Herbal medicines
have been used over 5000 years and their enduring popularity may be attributed to the perception
that they cause minimal unwanted side effects. Discovering novel therapeutics from herbal medicines
remains a promising approach for drug development [2].
Cardiotonic steroids (CTSs) are a class of natural products that are commonly found in many
herbal plants. CTSs have been used for the treatment of cardiac diseases since Hippocrates and the
mechanisms of action are associated with Na/K-ATPase [3]. Recently, researchers found that a signal
cascade involving EGFR and PLC could be initiated by CTSs via their binding to Na/K-ATPase,
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resulting in an increase in collagen expression [4–6]. These findings suggest that CTSs may be
potential wound healing therapeutics by stimulating collagen synthesis, which is one of the most
important mechanisms in wound healing [7]. A previous study revealed that digoxin significantly
promoted wound healing by stimulating collagen synthesis and could be a potential wound healing
therapeutics [4]. After application of digoxin in olive oil on the excisional wounds in rats, wound
closure was significantly accelerated and a greater amount of dermal collagen was detected in the
wound area as compared with the vehicle control group. This study also demonstrated that olive oil
was necessary for the wound healing effect of digoxin.
CTSs can be divided into two distinct groups: cardiac glycosides (e.g., digoxin, ouabain, and digitoxin)
and cardiac aglycones (e.g., digoxingenin, ouabagenin, and digitoxigenin). Digitoxigenin is a cardiac
aglycone and it has more favorable physicochemical properties for drug delivery than digoxin, such as
smaller molecular weight and greater lipophilicity. Particularly, our pervious in vitro Na/K-ATPase
assay study showed that digitoxigenin inhibited the Na/K-ATPase with an inhibitory minimum
concentration (IC50 ) of 0.22 µM, which was lower than the IC50 for digoxin of 1.76 µM (data not
shown). This implies that digitoxigenin showed more affinity with Na/K-ATPase and may be a better
candidate for wound healing than digoxin. Despite the stimulated collagen synthesis and wound
healing effect of digoxin [4], it is not known if digitoxigenin exhibits the similar wound healing effect
as cardiac glycosides, like digoxin. Therefore, it is necessary to prove that digitoxigenin can stimulate
collagen synthesis and accelerate the wound closure.
Olive oil was found as a carrier necessary for the delivery of digoxin due to its lipophilicity [4].
As digitoxigenin is relatively hydrophobic with a measured olive oil/water partition coefficient of
17.75 [8], olive oil is expected to be an important carrier for the wound healing effect of digitoxigenin.
However, the drug in olive oil solution is inconvenient for topical application. Therefore, we developed
a topical formulation capable of loading both digitoxigenin and olive oil. Alginate has been used
in wound healing due to its unique gelling property in contact with polyvalent cations, such as
calcium [9]. Calcium alginate-based wound dressings are commercially available. After application
of the calcium alginate-based wound dressings on wounds, sodium from the wound’s exudates and
calcium from alginate dressings will undergo ion exchange, forming a soluble sodium alginate gel.
Alginate was thus selected to formulate the digitoxigenin formulation and olive oil was a vehicle to
dissolve digitoxigenin.
The objective of this study was to evaluate the possibility of digitoxigenin and its topical
formulation for wound healing effect. We first examined if digitoxigenin could stimulate collagen
synthesis in human dermal fibroblasts and exert the wound healing activity in a rat excisional wound
model. Next, the microspheres containing both digitoxigenin and olive oil were prepared using
alginate and the microsphere-dispersed gel formulation was investigated for in vitro drug release and
in vivo wound healing effect.
2. Materials and Methods
2.1. Materials
Digitoxigenin and olive oil (highly refined, low acidity) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Alginic acid sodium salt (low viscosity) was from MP Biomedicals (Solon,
OH, USA). Tween 85 (Acros Organics, Morris, NJ, USA) and Span 85 (Sigma-Aldrich, St. Louis,
MO, USA) were used in the preparation of digitoxigenin formulations. Other reagents used were
isooctane (Acros Organics, Morris, NJ, USA) and calcium chloride dehydrate (Fisher Scientific,
Springfield, NJ, USA). Phosphate buffered saline (PBS) of pH 7.4 was prepared by dissolving PBS
tablets (MP Biomedicals, Solon, OH, USA) in deionized water, and sodium azide (Acros Organics,
Morris, NJ, USA) was added at a concentration of 0.02% (w/v) as a bacteriostat. High performance
liquid chromatography (HPLC) grade methanol, water, and formic acid were purchased from Fisher
Scientific (Pittsburgh, PA, USA).
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2.2. Animals
Sprague-Dawley rats (male and female, 240–260 g) were purchased from Hilltop Lab Animals
(Scottdale, PA, USA). All of the experiments were conducted under the approval of the Institutional
Animal Care and Use Committee at Marshall University.
2.3. Stimulation of Collagen Synthesis in Human Dermal Fibroblast Cells
In vitro stimulation of collagen synthesis activity of digitoxigenin was investigated in human
dermal fibroblast (HDF) cells (product No. CCD-1072Sk, ATCC No: CRL-2088) supplied from
ATCC (Manassas, VA, USA). HDF cells were cultured with ISCOVE’S modified Dulbecco’s medium
(Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS, Atlanta Biologicals,
Flowery Branch, GA, USA). After the HDF cells grew to confluence, the medium was removed and the
cells were incubated with the medium containing 1% FBS for 12 h to avoid any possible interference due
to growth factors present in the serum. The cells were then treated with the medium (negative control,
containing 10% FBS but no digitoxigenin or ouabain), ouabain (positive control, 1 nM dissolved in the
medium containing 10% FBS), or digitoxigenin (0.1, 1 or 10 nM dissolved in the medium containing
10% FBS). After treatment for 24 h, cell lysates were prepared by washing the cells twice with ice-cold
PBS, followed by incubating them on ice for 20 min with a lysis buffer containing 50 mM HEPES
sodium, 50 mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.25% Na-Dexycholate, and protease and
phosphatase inhibitors. Cell lysates were collected and used immediately or stored at −80 ◦ C.
Western blot analysis was performed as described previously [6]. Briefly, cell lysates were
dissolved in loading buffer and proteins (10 µg/lane) were separated by SDS-PAGE using 8% Tris·HCl
ready precast gels (Bio-Rad, Hercules, CA, USA). After separation, proteins were transferred onto
polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% non-fat dry
milk (Bio-Rad, Hercules, CA, USA) in Tris-buffered saline that was supplemented with 0.05% Tween
20 (TBS-T) at room temperature for 1 h and then incubated with primary antibody (Goat-Anti-Type 1
Collagen-UNLB, Southern Biotech, Birmingham, UK) in blocking buffer at 4 ◦ C overnight. After being
washed in TBS-T, the membranes were incubated with secondary antibody in the blocking buffer
for 2 h at room temperature. After being washed in TBS, the membranes were developed with ECL
(Amersham Biosciences, Piscataway, NJ, USA). For loading controls, tubulin was probed. The images
captured on X-ray film were scanned and quantified by using Image J software.
2.4. Preparation of Digitoxigenin Microspheres
Digitoxigenin-loaded alginate microspheres were prepared by an emulsification technique with
modifications from the literatures [10,11]. Briefly, 250 µL 150 µg/mL digitoxigenin in olive oil were
dispersed in 5 g 2% w/w alginate solution using a homogenizer (Polytron PT 2100; Kinematica, Lucern,
Switzerland) at 11,000 rpm for 1 min. After the addition of 7.5 g isooctane containing 0.254 g Span
85 into the alginate solution followed by homogenization for 1 min, 1 g aqueous solution containing
0.136 g Tween 85 was added and homogenized for 1 min. Two grams of 25% calcium chloride were
added and the mixture was homogenized for 10 min to allow for the calcium to react with the sodium
alginate. Isooctane was decanted after centrifugation at 4400 rpm for 5 min and microspheres were
collected. The microspheres were washed with 2 mL deionized water three times and dried at room
temperature for the in vitro and in vivo studies.
2.5. Digitoxigenin Content Assay
The amounts of digitoxigenin loaded to the microspheres were determined by extracting
digitoxigenin from the microspheres and subsequent assaying by LC-MS/MS. Microspheres of 0.03 g
were dispersed in 1 mL PBS and then sonicated in an ultrasonic bath for 1 h. The mixture was
centrifuged at 10,000 rpm for 5 min and the supernatant was collected. The residue was subjected
to two more extractions and the supernatants were collected. Digitoxigenin was extracted from
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the supernatant with methanol and analyzed by LC-MS/MS. The amount of digitoxigenin in the
microspheres was determined.
2.6. In Vitro Release Study
Digitoxigenin released from the microsphere was determined using Franz diffusion cells with
an effective diffusion area of 0.64 cm2 and a MF-Millipore membrane (0.45 µm) that was sandwiched
between the donor and receptor compartments. The digitoxigenin-loaded microspheres of 0.05 g were
dispersed in 600 µL 2% (w/w) alginate solution containing 0.9% (w/v) NaCl and then loaded to the
donor chamber. The receptor solution was 5 mL PBS containing 0.02% (w/v) sodium azide and was
kept at 37 ◦ C ± 1 ◦ C. One milliliter of the receptor solution was collected at 20 and 40 min as well as at
1, 1.5, 3, 3.5, 4, and 7 h, with replacement of a fresh receptor solution to maintain the volume of the
receptor solution constant. The samples were assayed for digitoxigenin by LC–MS/MS. The amounts
of digitoxigenin released from the microspheres were determined and plotted versus the time.
2.7. Wound Healing Study
The rats were randomly divided into seven groups and seven rats for each group. The rats
were anesthetized with intraperitoneal injection of ketamine/xylazine (30–50 mg/kg & 5–10 mg/kg,
respectively). Prior to wound creation, buprenorphine was administered intraperitoneally
(0.01–0.05 mg/kg). The hair in an area of about 500 mm2 in the dorsal skin of the rat was shaved and
the hair-removed area was wiped with alcohol swab (Becton-Dickinson, Franklin Lakes, NJ, USA).
Full-thickness skin biopsy was performed with an 8.0-mm sterile punch biopsy (Acu-punch, Acuderm,
Fort Lauderdale, FL, USA). Two symmetric lesions with at least 15 mm apart were made in each rat
and received two different treatments immediately after wound creation; one wound was treated with
a vehicle and the other with a digitoxigenin-loaded formulation. The seven treatment groups were
(1) untreated (no vehicle or digitoxigenin-loaded formulation applied), (2) olive oil, (3) 2% w/w alginate
solution containing 0.9% sodium chloride, (4) digitoxigenin in olive oil (1 ng/mL), (5) digitoxigenin in
olive oil (0.1 ng/mL), (6) digitoxigenin in 2% alginate solution (1 ng/mL), and (7) digitoxigenin-loaded
microspheres in 2% alginate solution containing 0.9% sodium chloride. The digitoxigenin microsphere
gels were freshly prepared by dispersing 10 mg microspheres in 1 mL 2% w/w alginate solution
containing 0.9% NaCl.
The vehicle or the digitoxigenin-loaded formulations of 100 µL was first applied to a Curad clear
water proof bandage (Medline Industries, Mundelein, IL, USA), which was cut into two rectangle
pieces (1.25 × 0.75 cm). The wounds were immediately covered with the Curad bandages after wound
creation and an adhesive porous tape (Kendall, Covidien, Mansfield, MA, USA) was applied to hold
the Curad bandage in place. To ensure the bandages were not removed by rats and wound contraction
was inhibited in the wound healing process, additional self-adhesive wrap (Coban, 3M Health Care,
St. Paul, MN, USA) and adhesive tapes were applied. At 3, 7 and 10 days following the wounding, the
bandages were gently removed and digital photographs were taken immediately. A new bandage was
applied to the wounds, but no vehicle or digitoxigenin was added. Photographs were analyzed with
Image J and the percentage of wound open was calculated as the remaining wound area with respect
to the initial wound area.
2.8. LC–MS/MS Assay
The LC–MS/MS assay method was developed and modified from the literature [8]. The LC–MS/MS
system consisted of an Agilent 1290 series UHPLC system and an Agilent 6490 Triple Quadrupole
(QqQ) mass spectrometer equipped with Agilent Jet-Stream ESI interface. Chromatographic separation
was carried out on an Agilent Poroshell 120 EC-C18 column (2.1 × 50 mm I.D., 2.7 µm) with an
Agilent UHPLC guard cartridge (2.1 × 5 mm I.D., 2.7 µm) at room temperature with a flow rate
of 200 µL/min. The mobile phase consisted of water (0.1% formic acid)–methanol (0.1% formic
acid) (40:60, v/v), and the total run time was 4.0 min. ESI source was operated in the positive
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3.2. In Vitro Release Study
Figure 2 presents the amounts of digitoxigenin released from the microspheres over time.
Digitoxigenin was gradually released from the microspheres. At 7 h, about 35 ng or 60% of
digitoxigenin was released. These results implied that the microspheres could be used as a delivery
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binding properties. With increasing the concentration of digitoxigenin applied, the receptor binding
sites can become saturated, and therefore, the response will not increase with dose. While it is not
known if the IC50 for the Na/K-ATPase pump inhibition can reflect the binding capability of CTS
with the Na/K-ATPase as the receptor and at which concentration the receptor binding sites will
be saturated with digitoxigenin, the lower IC50 value for digitoxigenin (0.22 µM) than for digoxin
(1.76 µM) (unpublished data) might suggest that the saturation would occur at a lower concentration
of digitoxigenin. The unobserved dose-dependent response might be also related to the large data
variability and the possible involvement of other signal transductions to stimulate collagen synthesis
in HDF following exposure to digitoxigenin [15].
4.2. Wound Healing Effect of Digitoxigenin
In the previous study with digoxin [4], olive oil was found necessary for the successful delivery
of digoxin for wound healing. In our animal study, olive oil was thus also used as a vehicle for
digitoxigenin and its formulation. In addition, alginate was selected for topical formulation of
digitoxigenin due to its desirable properties for wound healing [16]. To examine the feasibility
of using digitoxigenin for wound healing, we first performed the in vivo wound healing studies using
digitoxigenin in olive oil or alginate solution. Figures 3 and 4 show that digitoxigenin at the doses
of 0.01 and 0.1 ng in olive oil significantly decreased the wound open when compared with the olive
oil control group and the wound healing was promoted with the digitoxigenin treatment for 3 days.
Digitoxigenin in alginate solution at the dose of 0.1 ng also accelerated the wound healing as evidenced
by the decreased wound open three days after wounding as compared with the alginate control group.
After removal of digitoxigenin from the wound site at day 3 after wounding, the wound healing effect
of digitoxigenin was not maintained. These results suggest that digitoxigenin increased the wound
healing when it was applied. The finding in this study is consistent with the results in the previous
study where digoxin was dosed over nine days post wounding [4]. Repeated dosing is needed to exert
the wound healing effect for a prolonged period of time and warrants further study.
As a topical formulation with the capability of loading both olive oil and digitoxigenin is
desired for topical administration, the digitoxigenin microspheres dispersed in an alginate gel were
thus formulated and tested for wound healing in vivo. It can be seen from Figures 3 and 4 that
digitoxigenin-loaded microsphere gels also exerted wound healing effect at day 3 after wounding.
The accelerated wound healing was not observed at days 7 and 10 when no digitoxigenin formulation
was applied. These results suggest that digitoxigenin was released from the microspheres in vivo to
elicit the wound healing effect. The alginate microsphere-based gel might be a potential platform for
topical formulation of digitoxigenin. The formulation might be further manipulated to prolong the
wound healing effect.
4.3. Feasibility and Potential of Using Digitoxigenin for Wound Healing
The results from the present study suggest that digitoxigenin exhibited the wound healing activity
at a dose as low as 0.01 ng. This is in contrast with the dose of digoxin (2.3 ng) that was used for
wound healing in the previous study [4]. Such a low effective dose would be highly desirable for
clinical application of digitoxigenin. It is well known that systemic administration of CTS compounds,
like digoxin, increases the risk of cardiac toxicity, presenting a serious problem that requires close
therapeutic dose monitoring. The cardiac toxicity is attributed to the ion pumping function of the
Na/K-ATPase that is related to the levels of CTSs in the systemic circulation [17]. Topical application of
digitoxigenin for wound healing could allow for using low doses at the wound site while minimizing
systemic absorption of digitoxigenin and thus preventing systemic side effects. Moreover, it is also
known that the concentrations of CTS needed to activate the receptor function of the Na/K-ATPase are
much lower than those that are needed to inhibit the pump function of the Na/K-ATPase [18]. It can
be expected that the effective doses of digitoxigenin for wound healing may be too low to inhibit the
pump function of the Na/K-ATPase, and subsequently to result in the pump-related cardiac toxicity.
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Many CTSs have been clinically used at the concentrations far beyond what was used in the topical
administration [19]. To this end, digitoxigenin might be a potential therapeutic for wound healing and
the cardiac toxicity would not be a major concern.
While this study has demonstrated the feasibility of using topical digitoxigenin for wound healing,
there were limitations in the study. First, histological and biochemical assays were not performed in the
present study to examine the roles of digitoxigenin in wound healing. Increased collagen deposition
and wound healing should be confirmed in vivo by analyzing wound tissues. Our unpublished
data from a separate research using digitoxigenin and a wound model of rats suggested the effect of
digitoxigenin on collagen deposition in vivo (data not shown). Vascularization and other mechanisms
may be involved in the wound healing and should be investigated in future studies to reveal the
underlying mechanisms of digitoxigenin in wound healing. Second, single dosing regimen was used
in our present study and the wound healing effect was only observed when digitoxigenin was applied.
It would be impossible to evaluate the overall wound healing outcomes following the single dose of
topical digitoxigenin and to elucidate the mechanisms of action, given the complex wound healing
process with several overlapped phases. Repeated doses over a long period of time would be needed
to confirm the efficacy of digitoxigenin. Third, while we had taken special procedures to minimize
wound contraction in rats, it would be worthwhile to further determine the effect of digitoxigenin on
wound healing in animal models better resembling the wound healing process in humans. To sum
up, the present study implies the feasibility of digitoxigenin and its topical formulation for wound
healing. However, digitoxigenin as a promising wound healing candidate warrants future studies to
validate the efficacy and better understand the mechanisms. This was the first investigation of using
digitoxigenin in wound healing, and would present a new direction to explore novel therapeutics for
wound healing.
5. Conclusions
This was a pilot feasibility study to determine (1) if digitoxigenin, a cardiac aglycone, had effects
on collagen synthesis in vitro and wound closure in vivo as previously reported for digoxin, a cardiac
glycoside; and, (2) if a formulation could be developed for topical application. The results showed
that digitoxigenin increased collagen synthesis in human dermal fibroblasts and decreased wound
open in a rat excisional wound model as compared with the vehicle controls. The digitoxigenin-loaded
microsphere gel exerted the wound healing effect similar to digitoxigenin in vehicles and could serve
as a convenient dosage form for topical application. However, topical digitoxigenin need further
investigation to prove efficacy and understand underlying mechanisms. While this single dosing
study could provide an initial understanding of the effect of digitoxigenin in the early phase of wound
healing, multiple dosing studies will be necessary to understand the effect of digitoxigenin in the
later phase of a wound healing process. The results from this study imply that digitoxigenin might be
a promising candidate for future development to be a wound healing therapeutics.
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